Effectiveness and Practicality of eKTANG as a Digital Treatment for Diabetes and Relevant Influence Factors

Xiaohua Lu 1, Dalong Guo 2, Lie Feng 1, Yan Zhou 3, Chuangbiao Zhang 1, *Jiaying Li 1, Yin Jiang 2

1. Department of Endocrinology, First Affiliated Hospital of Jinan University, Guangzhou, China
2. Zhejiang Idoctor Health Technology Company Limited, Hangzhou, China
3. Department of Interventional Orthopaedics, First Affiliated Hospital of Jinan University, Guangzhou, China

*Corresponding Author: Email: j5fpvc@163.com

(Received 10 Dec 2020; accepted 15 Feb 2021)

Abstract
Background: This work explored the effect of eKTANG, a new healthcare mode for diabetes patients, on diabetes management.

Methods: Allowing general utilization of medical service and health management based on Internet, eKTANG obtained the precise data like blood glucose and blood pressure examined by an intelligent glucometer, from which doctors and the nursing team will promptly analyze the data and return feedback to the patients. In our study, overall 204 patients receiving eKTANG management over 3 months in First Affiliated Hospital of Jinan University from May 2019 to Aug 2020 were enrolled as the research objects, with data collected from patient records.

Results: Through the biochemical test on relevant indexes of blood glucose, it was observed that FBG, PBG, HbA1c, TG, TC, LDL levels after management were lower than before whereas HDL expression after were lower than before. Contrasted with substandard group, standard group performed younger age, lower proportion of the married, decreased proportion of microvascular and macrovascular complications, longer course of disease, more frequent glucose monitoring, declined time of hyperglycemia and time of alarms, elevated time of euglycemia, increased proportion of diet control, more amount of exercise and higher compliance, as the number of patients choosing oral medicine in standard group was more than substandard group. The course of disease and time of hyperglycemia were risk factors of HbA1c standard reaching whereas frequency of glucose monitoring (≥1 time/week) and time of euglycemia were protective factors.

Conclusion: eKTANG effectively improved diabetes management.

Keywords: Diabetes; Effectiveness and precision; Internet remote platform

Introduction

Diabetes is a metabolic disorder characterized by an aberrant long-term rise of blood glucose level (1). In 2017, there were about 4,000,000 people dying from diabetes, accounting for 10.7% of all-cause deaths globally (2). Furthermore, the incidence of diabetes continuously increases and the
number of adult diabetes patients worldwide is predicted to reach nearly 700,000,000 by 2045 (3-5). As the largest diabetes country with 25% of diabetes patients around the world living in China, the similar trend is also found in China and goes even farther (6). With the long-term treatment, high morbidity and various complications, diabetes results in not only the negative physical and mental influence but also the huge economic (7-11). Hyperglycemia, a main sign for diabetes and a major cause of diverse complications in diabetes, is correlative to a poor prognosis of diabetes patients (12). Hence, blood glucose control is pivotal for ameliorating outcome of diabetes patients.

In developed countries, diabetes treatment and control are patient-centered, focusing more on patient self-management and lifestyle modification rather than drug therapy and physician intervention (3, 13). Nevertheless, in developing countries, the diabetes is not interfered until the initiation of the disease or even diabetes complications, with the treatment based mostly on the medication (3, 14, 15). In China, although more attention has been paid into that patient-centered approach for diabetes treatment and control and a certain effect has been achieved in several studies (3, 16-19), diabetes self-management still remains in its infancy.

The eKTANG is a new healthcare mode for diabetes patients. Combining Internet technology with healthcare, eKTANG allows general utilization of medical service and health management based on Internet. Through an intelligent glucometer, the precise data like blood glucose and blood pressure are transmitted to eKTANG background, from which doctors and the nursing team will promptly analyze the data and return feedback to the patients. The application (APP) enables remote patients to realize diabetes treatment and control via self-management in multiple aspects (exercise, diet, etc.) under the professional guidance of the medical team. We aimed to evaluate the implementation effect of eKTANG on diabetes patients.

Materials and Methods

Subjects and data
Cases of diabetes receiving eKTANG management over three months in First Affiliated Hospital of Jinan University from May 2019 to Aug 2020 were enrolled as the research objects. This study was approved by the Ethics Committee of First Affiliated Hospital of Jinan University (FA20190505608), with informed consent signed. Clinical data in the research were collected from patient records. Overall, 210 patients were incorporated into the research, among whom 6 patients were excluded due to lack of clinical data. Eventually, data pertaining to 204 patients were included in the analysis.

Implementation plan
Doctors instructed their own patients in downloading eKTANG APP equipped with a customized intelligent glucometer, with primary nurses responsible for teaching patients relevant information. After discharge from the hospital, patients were required to record each index through the APP, based on which doctors formulated a corresponding scheme that was then transmitted to the nursing team for managing patients. For blood glucose emergency/abnormality (blood glucose ≤ 3.9 mmol/L or ≥ 16.9 mmol/L), the alarm would be sounded for a timely intervention.

Outcome measures
The application effect of the eKTANG was assessed mainly according to the changes in the following indicators from May 2019 to Aug 2020: self-management behavior, relevant indexes before and after management and analysis of blood glucose standard and hypoglycemia.

Self-management behavior
The data of self-management behaviors were collected through follow-up by telephone, outpatient service and APP background, including frequency of glucose monitoring, time of glucose monitoring, time of hypoglycemia (patients
whose blood glucose is lower than the minimum target set by doctors), time of hyperglycemia (patients whose blood glucose is lower than the maximum target set by doctors), time of euglycemia, time of alarms (blood glucose ≤ 3.9 mmol/L or ≥ 16.9 mmol/L), diet control, exercise, compliance, use of hypoglycemic agents, frequency of return visit and management (patients taking eKTANG management by self or caregiver).

**Relevant indexes before and after management**

FBG, PBG, HbA1c, SBP, DBP, BMI, TG, TC, LDL, HDL, ALT and Cr were all biochemical indexes associated with blood glucose, which were measured by the customized intelligent glucometer and later automatically uploaded to the background of APP for data collection.

**Analysis of blood glucose standard and hypoglycemia**

Blood glucose standard-reaching rate, level of blood glucose standard-reaching rate, time of hypoglycemia and hypoglycemia level were analyzed in this part, with the relevant data obtained from background of APP through measurement by glucometer. Blood glucose standard-reaching rate was calculated as the number of diabetes with HbA1C < 7% divided by the total number of diabetes patients. The “hypoglycemia” in time of hypoglycemia and hypoglycemia level referred to the blood glucose ≤ 3.9 mmol/L.

**Statistical analysis**

Statistical analysis was made by SPSS 20.0 software (SPSS, Chicago, IL, USA). Measurement data was performed as the means ± standard deviation, as the relevant indexes before and after management contrasted by Student’s t test. Enumeration data were presented as case number. Univariate analysis was evaluated through chi-squared test, whereas multivariable analysis was done using binary logistic regression analysis. P < 0.05 implicated a statistically significance.

**Results**

**Patient characteristics**

Table 1 shows the clinical data (follow-up time, age, gender, marital status, education background, residence, monthly income, Internet time, course of disease, family history of diabetes, smoking history, drinking history, microvascular complication and macrovascular complication) of patients.

| Variables                     | Mean value/N (n=204) | Proportion (%) |
|-------------------------------|----------------------|----------------|
| Follow-up time (Days)         | 211.7±129.0          |                |
| Age (yr)                      | 52.6±14.4            |                |
| Gender                        |                      |                |
| Male                          | 118                  | 57.8           |
| Female                        | 86                   | 42.2           |
| Marital status                |                      |                |
| Married                       | 189                  | 92.6           |
| Divorced/widowed              | 2                    | 1.0            |
| Single                        | 13                   | 6.4            |
| Education background          |                      |                |
| Primary school or below       | 43                   | 21.1           |
| Junior high school            | 37                   | 18.1           |
| High school or technical sec- | 72                   | 35.5           |
| ondary school                 |                      |                |
| Junior college or above       | 72                   | 35.5           |
| Residence                     |                      |                |
| Urban                         | 174                  | 85.3           |
| Suburb                        | 30                   | 14.7           |
**Self-management behaviors**

Table 2 presents self-management behaviors comprising frequency of glucose monitoring, time of glucose monitoring, time of hypoglycemia, time of hyperglycemia, time of euglycemia, time of alarms, diet control, exercise, compliance, use of hypoglycemic agents, frequency of return visit and management.

| Variables                                      | Mean value/N (n=204) | Proportion (%) |
|------------------------------------------------|----------------------|----------------|
| **Frequency of glucose monitoring**            |                      |                |
| (times/month)                                  |                      |                |
| No monitoring                                  | 17                   | 8.3            |
| <1 time/month                                  | 10                   | 4.9            |
| ≥1 time/month                                  | 35                   | 17.2           |
| ≥1 time/week                                   | 142                  | 69.6           |
| **Time of glucose monitoring**                 | 251.7±219.9          |                |
| Time of hypoglycemia                           | 6.8±14.5             |                |
| Time of hyperglycemia                          | 61.4±78.7            |                |
| Time of euglycemia                             | 183.5±173.5          |                |
| Time of alarms                                 | 8.3±20.3             |                |
| Diet control                                   |                      |                |
| Yes                                            | 188                  | 92.2           |
| No                                             | 16                   | 7.8            |
| **Exercise**                                   |                      |                |
| No exercise                                    | 24                   | 11.8           |
| ≤150 min/week                                  | 56                   | 27.5           |
| ≥150 min/week                                  | 124                  | 60.8           |
| Compliance                                     |                      |                |
**EKTANG management improved relevant indexes of diabetes patients**

As shown in Table 3, the levels of FBG, PBG, HbA1c, TG, TC, LDL after management were prominently lower than those before management whereas HDL expression after management obviously declined in comparison with that before management.

### Table 3: Comparison of relevant indexes before and after management

| Indexes            | Before management | After management | t      | P     |
|--------------------|-------------------|------------------|--------|-------|
| FBG (mmol/L)       | 8.4±3.7           | 7.0±2.2          | 5.296  | 0.000 |
| PBG (mmol/L)       | 11.3±5.5          | 8.7±3.2          | 6.614  | 0.000 |
| HbA1c (%)          | 9.8±3.1           | 6.8±1.4          | 12.524 | 0.000 |
| SBP (mmHg)         | 128.5±15.1        | 126.2±14.5       | 2.371  | 0.019 |
| DBP (mmHg)         | 75.5±13.4         | 75.6±12.8        | -0.104 | 0.917 |
| BMI (kg/m²)        | 24.5±4.1          | 24.1±4.0         | 2.974  | 0.003 |
| TG (mmol/L)        | 2.3±2.9           | 1.6±1.4          | 3.888  | 0.000 |
| TC (mmol/L)        | 4.9±1.3           | 4.4±1.1          | 5.673  | 0.000 |
| LDL (mmol/L)       | 2.8±0.9           | 2.5±0.9          | 5.361  | 0.000 |
| HDL (mmol/L)       | 1.1±0.3           | 1.2±0.4          | -3.166 | 0.002 |
| ALT (U/L)          | 34.0±39.1         | 26.4±16.0        | 2.800  | 0.006 |
| Cr (μmol/L)        | 73.5±60.6         | 74.5±36.4        | -0.298 | 0.766 |

**Analysis of blood glucose standard and hypoglycemia in patients**

Table 4 exhibits patients’ conditions of blood glucose standard and hypoglycemia, which consists of blood glucose standard-reaching rate, level of blood glucose standard-reaching rate, time of hypoglycemia and hypoglycemia level.
Table 4: Analysis of blood glucose standard and hypoglycemia in patients

| Variables                                          | Mean value/N (n=204) | Proportion (%) |
|----------------------------------------------------|----------------------|----------------|
| Blood glucose standard-reaching rate (%)           | 71.5±21.3            |                |
| Level of blood glucose standard-reaching rate      |                      |                |
| &lt;60%                                            | 56                   | 27.5           |
| 60-80%                                             | 65                   | 31.9           |
| &gt;80%                                            | 83                   | 40.7           |
| Time of hypoglycemia                               | 3.3±6.9              |                |
| Hypoglycemia level                                 |                      |                |
| Unhappen                                           | 81                   | 39.7           |
| &lt;3.9 mmol/L                                     | 49                   | 24.0           |
| ≤3.0 mmol/L                                        | 74                   | 36.3           |

The factors related to HbA1c standard reaching

The univariate analysis presented that there was no marked difference in gender, education background, residence, monthly income, internet time, family history of diabetes, smoking history, drinking history, time of glucose monitoring, time of hypoglycemia, frequency of return visit, management and hypoglycemia level between standard group and substandard group. Compared with substandard group, patients of standard group performed the younger age as well as the lower proportion of the married. In addition, the course of disease in standard group was longer than substandard group. In addition, decreased proportion of microvascular and macrovascular complications were observed in standard group when compared with substandard group. Moreover, glucose monitoring of patients in standard group was more frequent than substandard group, as time of hyperglycemia and time of alarms in standard group dramatically lower than substandard group while time of euglycemia in standard group was higher than substandard group. Besides, patients of standard group possessed elevated proportion of diet control, more exercise as well as higher compliance in comparison with substandard group. Using hypoglycemic agents was also a factor with significant difference between standard group and substandard group, as the number of patients choosing oral medicine in standard group was more than substandard group (Tables 5-7).

Table 5: Univariate analysis

| Variables              | Standard (n=136) | Substandard (n=68) | P        |
|------------------------|------------------|--------------------|----------|
| Mean value/N           |                  |                    |          |
| Age (yr)               | 50.1±15.1        | 57.6±11.4          | 0.000    |
| Gender (male)          | 79               | 39                 | 0.920    |
| Marital status         |                  |                    | 0.082    |
| Married                | 123              | 66                 |          |
| Divorced/widowed       | 1                | 1                  | 0.124    |
| Single                 | 12               | 1                  |          |
| Education background   |                  |                    |          |
| Primary school or below| 25               | 18                 |          |
| Junior high school     | 24               | 13                 |          |
| High school or technical secondary school | 35           | 17                 |          |
| Junior college or above| 52               | 20                 |          |

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
| Residence          |                   |                   |       |       |
|--------------------|-------------------|-------------------|-------|-------|
| Urban              | 115               | 84.6              | 59    | 86.8  |
| Suburb             | 21                | 15.4              | 9     | 13.2  |
| Monthly income     |                   |                   |       |       |
| <3000              | 30                | 22.1              | 23    | 33.8  |
| 3000~5000          | 18                | 13.2              | 8     | 11.8  |
| >5000              | 88                | 64.7              | 37    | 54.4  |
| Internet time      |                   |                   |       |       |
|                    | 6.2±4.0           | 6.6±4.3           | 0.496 |       |
| Course of disease  |                   |                   |       |       |
| (years)            | 8.1±6.3           | 3.3±4.8           | 0.000 |       |

| Variables                        | Standard (n=136) | Substandard (n=68) | P     |
|----------------------------------|------------------|---------------------|-------|
|                                  | Mean value/N     | %                   | Mean value/N | %      |
| Family history of diabetes       |                   |                     | 0.674 |       |
| Yes                              | 44               | 32.4                | 24    | 35.3  |
| No                               | 92               | 67.6                | 44    | 64.7  |
| Smoking history (Yes)            | 22               | 16.2                | 14    | 20.6  |
| Drinking history (Yes)           | 22               | 16.2                | 12    | 17.6  |
| Microvascular complication       |                   |                     | 0.002 |       |
| Yes                              | 61               | 44.9                | 46    | 67.6  |
| No                               | 75               | 55.1                | 22    | 32.4  |
| Macrovascular complication       |                   |                     | 0.039 |       |
| Yes                              | 42               | 30.9                | 31    | 45.6  |
| No                               | 94               | 69.1                | 37    | 54.4  |
| Frequency of glucose monitoring  |                   |                     | 0.000 |       |
| (times/month)                    |                   |                     |       |       |
| No monitoring                    | 6                | 4.4                 | 11    | 16.2  |
| <1 time/month                   | 6                | 4.4                 | 4     | 5.9   |
| ≥1 time/month                   | 16               | 11.8                | 19    | 27.9  |
| ≥1 time/week                    | 108              | 79.4                | 34    | 50.0  |
| Time of glucose monitoring       | 230.2±189        | 6.8±12.4            |       |       |
|                                 | .9               | 95.8±96.1           |       |       |
| Time of hypoglycemia            | 6.8±15.4         | 95.8±96.1           | 0.989 |       |
| Time of hyperglycemia           | 44.2±61.9        | 95.8±96.1           | 0.000 |       |

Through multiple regression analysis, we discovered that course of disease, frequency of glucose monitoring (≥1 time/week), time of hyperglycemia as well as time of euglycemia could affect HbA1c standard reaching in the different way, as the course of disease and time of hyperglycemia were risk factors of HbA1c standard reaching whereas frequency of glucose monitoring (≥1 time/week) and time of euglycemia were protective factors HbA1c standard reaching (Table 8).
Table 7: Univariate analysis

| Variables                  | Standard (n=136) | Substandard (n=68) | P  |
|----------------------------|------------------|--------------------|----|
|                            | Mean value/N     | Mean value/N       |    |
| **Time of euglycemia**     | 211.4±191.       | 127.6±112.8        | 0.000 |
| **Time of alarms**         | 5.4±16.7         | 14.1±25.1          | 0.010 |
| **Diet control**           |                  |                    | 0.000 |
| Yes                       | 134              | 54                 | 79.4 |
| No                        | 2                | 14                 | 20.6 |
| **Exercise**              |                  |                    | 0.001 |
| No exercise               | 11               | 13                 | 19.1 |
| ≤150 min/week             | 30               | 26                 | 38.2 |
| ≥150 min/week             | 95               | 29                 | 42.6 |
| **Compliance**            |                  |                    | 0.001 |
| Yes                       | 121              | 60                 | 88.2 |
| No                        | 3                | 8                  | 11.8 |
| Did not take medicine     | 12               | 0                  | 0.0  |
| **Use of hypoglycemic agents** |            |                    | 0.003 |
| Oral medicine             | 83               | 36                 | 52.9 |
| Insulin                   | 10               | 6                  | 8.8 |
| Oral medicine+ insulin    | 31               | 26                 | 38.2 |
| Life intervention         | 12               | 0                  | 0.0 |
| **Frequency of return visit** |                |                    | 0.104 |
| No visit                  | 3                | 3                  | 4.4 |
| Every 2-3 months          | 81               | 29                 | 42.6 |
| Monthly                   | 11               | 6                  | 8.8 |
| > 3 months                | 41               | 30                 | 44.1 |
| **Management**            |                  |                    | 0.590 |
| Self                      | 93               | 49                 | 72.1 |
| Caregiver                 | 43               | 19                 | 27.9 |
| **Hypoglycemia level**    |                  |                    | 0.239 |
| Unhappen                  | 54               | 27                 | 39.7 |
| ≤3.9 mmol/L              | 37               | 12                 | 17.6 |
| ≤3.0 mmol/L              | 45               | 29                 | 42.6 |

Table 8: Multiple regression analysis

| Variables                          | OR     | 95% CI      | P   |
|------------------------------------|--------|-------------|-----|
| Age (yr)                           | 1.015  | 0.975-1.057 | 0.458 |
| Marital status                     |        |             |     |
| Married                            |        |             |     |
| Divorced/widowed                   | 11.271 | 0.545-233.191 | 0.117 |
| Single                             | 0.524  | 0.031-8.821 | 0.654 |
| Course of disease (years)          | 1.129  | 1.040-1.226 | 0.004 |
| Microvascular complication         |        |             |     |
| Yes                                | 0.461  | 0.178-1.194 | 0.111 |
| No                                 |        |             |     |
| Macrovascular complication          |        |             |     |
| Yes                                |        |             |     |
| No                                 | 1.212  | 0.477-3.079 | 0.686 |
| Frequency of glucose monitoring    |        |             |     |

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
### Discussion

According to a former reporter, a collaborative daily self-management scheme is better for non-communicable disease (3). As a creative pattern integrating information technology and medical care, the remote management system for diverse diseases containing diabetes, which is believed to be a promising tool realizing the collaborative daily self-management, have already been studied in developed countries, with the efficiency and practicality validated by many clinical trials (3, 13, 19). However, few such researches have been operated in China.

The awareness and treatment rates of diabetes patients have significantly elevated in China those years, indicating a rising health consciousness of diabetes patients. Nevertheless, diabetes control is still poor (20). The reasons may be as follows: lacking tracking analysis of complete daily blood glucose data (especially discharged patients), doctors can only formulate medication regimen based on clinical experience, which impedes timely and accurate management for diabetes.

| (times/month) | No monitoring | ≥1 time/month | Time of hyperglycemia | Time of euglycemia | Time of alarms | Diet control | Exercise | Compliance | Use of hypoglycemic agents |
|---------------|---------------|---------------|------------------------|--------------------|----------------|--------------|----------|------------|--------------------------|
|               |               |               |                        |                    |                | Yes          | No       |            | Oral medicine            |
|               |               |               |                        |                    |                |              |          |            |                          |
|               |               |               |                        |                    |                |              |          |            | Insulin                  |
|               |               |               |                        |                    |                |              |          |            |                          |
|               |               |               |                        |                    |                |              |          |            | Oral medicine+insulin    |

CDSS-based u-healthcare service and the Internet-based blood glucose monitoring system both realized the better control for diabetes patients (21-23). Livongo for Diabetes Program is widely accepted as a successful example of diabetes management (24-27). EKTANG is an emerging Internet-based healthcare APP in China specially designed for diabetes patients. Generally, eKTANG has a similar mode to that of Livongo, through which data can be determined and delivered to a management team that will analyze the data and return in-time feedback to diabetes patients with medical support available. Furthermore, the alarm will sound when the specific events are monitored to remind patients and management team of timely and efficient intervention. The information shows that eKTANG pattern is in accord with the “five carriage” (medical treatment, kinesitherapy, dietotherapy, blood glucose monitoring, education of chronic disease) of diabetes management in China, suggesting the potential of eKTANG as a digital treatment in line with Chinese actual situations. Besides, consistent with researches above, our study observed that the blood glucose of diabetes patients were
improved after eKTANG management and it even achieved a greater effect with a more obvious decrease of HbA1c, implying the efficiency and superiority of eKTANG for diabetes control. A research about the role of 3Bs in diabetes patients reported that traditional management for diabetes in China mainly focuses on blood glucose control while ignores the crucial functions of blood pressure and lipid on diabetes treatment, which reveals the significance of 3Bs control during diabetes management (28). Agreeing with former other studies about the remote coaching system, Telemedicine and UCDC system (19, 29-31), eKTANG management not only improved blood glucose, but also ameliorated blood pressure and blood lipid in diabetes patients. Moreover, contrasted with the work about 3B approach for diabetes patients (28), eKTANG management fulfilled a better function on blood glucose control with a higher blood glucose standard-reaching rate, again supporting the positive effectiveness, practicality and superiority of eKTANG on managing and controlling diabetes. What’s more, during eKTANG management, patients reaching standard HbA1c level performed younger age, lower proportion of the married, decreased proportion of microvascular and macrovascular complications, longer course of disease, more frequent glucose monitoring, declined time of hyperglycemia and time of alarms, elevated time of euglycemia, increased proportion of diet control, more amount of exercise, higher compliance and a higher proportion of oral medicine taken, as the course of disease and time of hyperglycemia were risk factors of HbA1c standard reaching whereas frequency of glucose monitoring and time of euglycemia (≥1 time/week) were protective factors of HbA1c standard reaching, which further explained the mechanism of eKTANG management and provided some insights into eKTANG optimization.

Conclusion

The work confirmed the effectiveness and practicality of eKTANG on diabetes management, providing a promising treatment method for diabetes patients in China.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

This work was supported by the Science and Technology Plan Project of Guangzhou [No. 201707010245]; National Natural Science Foundation of China [No. 82073748]. The authors declare that there is no conflict of interest.

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Belwal T, Bisht A, Devkota HP, et al (2020). Phytopharmacology and Clinical Updates of Berberis Species Against Diabetes and Other Metabolic Diseases. Front Pharmacol, 11: 41.
2. Wang Z, Li X, Chen M (2018). Socioeconomic Factors and Inequality in the Prevalence and Treatment of Diabetes among Middle-Aged and Elderly Adults in China. J Diabetes Res, 2018: 1471808.
3. Cheng C, Xin G, Xiaoli W, et al (2019). Evaluation of the implementation and effect of the healthcare cloud information platform for diabetes self-management: A case study in Shanghai. Int J Health Plann Manage, 34(3): 986-997.
4. Leger T, He B, Azarnoush K, et al (2019). Dietary EPA Increases Rat Mortality in Diabetes Mellitus, A Phenomenon Which Is Compensated by Green Tea Extract. Antioxidants (Basel), 8(11): 526.
5. AlShwaimi E, Idrees M, Berri Z, El-Sakka H, Kujan O (2019). Association between Diabetes Mellitus and Periodontal Diseases: A Survey of the Opinions of Dental Professionals. Med Prin Pract, 28(2): 141-149.

6. Xu Y, Wang L, He J, et al (2013). Prevalence and control of diabetes in Chinese adults. JAMA, 310(9): 948-959.

7. India State-Level Disease Burden Initiative Diabetes Collaborators (2018). The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health, 6(12): e1352-e62.

8. Bilal U, Hill-Briggs F, Sánchez-Perruca I, Del Cura-González I, Franco M (2018). Association of neighbourhood socioeconomic status and diabetes burden using electronic health records in Madrid (Spain): the HeartHealthyHoods study. BMJ Open, 8(9): e021143.

9. Foos V, Wang K, McEwan P, et al (2019). Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value Health Reg Issues, 18: 36-46.

10. Jørgensen PG, Jensen MT, Biering-Sørensen T, et al (2018). Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus. J Am Heart Assoc, 7(19): e008856.

11. Li YC, Liu XT, Hu N, Jiang Y, Zhao WH (2013). [Disease burden on diabetes in China, 2010]. Zhonghua Liu Xing Bing Xue Za Zhi, 34(1): 33-36.

12. Cheng X, Gao W, Dang Y, et al (2013). Both ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. J Diabetes Res, 2013: 463740.

13. Crumby AS, Holmes ER, Rosenthal M (2018). Patient centered research to improve community involvement (PaRTICipate) in diabetes self-management: a conference series for developing collaborations between researchers, stakeholders, and patients. J Patient Rep Outcomes, 2(1): 47.

14. Jia W, Weng J, Zhu D, et al (2019). Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev, 35(6): e3158.

15. Weng J (2016). Evolution in the Chinese Diabetes Society Standards of Care for Type 2 Diabetes. Diabetes Metab Res Rev, 32(5): 440-441.

16. Cheng L, Sit JWH, Choi KC, et al (2018). Effectiveness of a patient-centred, empowerment-based intervention programme among patients with poorly controlled type 2 diabetes: A randomised controlled trial. Int J Nurs Stud, 79: 43-51.

17. Cheng L, Sit JWH, Choi KC, et al (2021). The effects of an empowerment-based self-management intervention on empowerment level, psychological distress, and quality of life in patients with poorly controlled type 2 diabetes: A randomized controlled trial. Int J Nurs Stud, 116: 103407.

18. Li X, Li Z, Liu C, et al (2017). Evaluation of the three-in-one team-based care model on hierarchical diagnosis and treatment patterns among patients with diabetes: a retrospective cohort study using Xiamen’s regional electronic health records. BMC Health Serv Res, 17(1): 779.

19. Wang G, Zhang Z, Feng Y, et al (2017). Telemedicine in the Management of Type 2 Diabetes Mellitus. Am J Med Sci, 353(1): 1-5.

20. Wang L, Gao P, Zhang M, et al (2017). Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA, 317(24): 2515-2523.

21. Kwon HS, Cho JH, Kim HS, et al (2004). Establishment of blood glucose monitoring system using the internet. Diabetes Care, 27(2): 478-483.

22. Lim S, Kang SM, Shin H, et al (2011). Improved glycemic control without hypoglycemia in elderly diabetic patients using the ubiquitous healthcare service, a new medical information system. Diabetes Care, 34(2): 308-313.

23. Cho JH, Chang SA, Kwon HS, et al (2006). Long-term effect of the Internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system. Diabetes Care, 29(12): 2625-2631.

Available at: http://ijph.tums.ac.ir
24. Whaley CM, Bollyky JB, Lu W, et al (2019). Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values. *J Med Econ*, 22(9): 869-877.

25. Yu JS, Xu T, James RA, Lu W, Hoffman JE (2020). Relationship Between Diabetes, Stress, and Self-Management to Inform Chronic Disease Product Development: Retrospective Cross-Sectional Study. *JMIR Diabetes*, 5(4): e20888.

26. Bollyky JB, Bravata D, Yang J, Williamson M, Schneider J (2018). Remote Lifestyle Coaching Plus a Connected Glucose Meter with Certified Diabetes Educator Support Improves Glucose and Weight Loss for People with Type 2 Diabetes. *J Diabetes Res*, 2018: 3961730.

27. Downing J, Bollyky J, Schneider J (2017). Use of a Connected Glucose Meter and Certified Diabetes Educator Coaching to Decrease the Likelihood of Abnormal Blood Glucose Excursions: The Livongo for Diabetes Program. *J Med Internet Res*, 19(7): e234.

28. Ji L, Hu D, Pan C, et al (2013). Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. *Am J Med*, 126(10): 925.e11-22.

29. Cho JH, Kwon HS, Kim HS, Oh JA, Yoon KH (2011). Effects on diabetes management of a health-care provider mediated, remote coaching system via a PDA-type glucometer and the Internet. *J Telemed Telecare*, 17(7): 365-370.

30. Carallo C, Scavelli FB, Cipolla M, et al (2015). Management of Type 2 Diabetes Mellitus through Telemedicine. *PloS One*, 10(5): e0126858.

31. Yoo HJ, Park MS, Kim TN, et al (2009). A Ubiquitous Chronic Disease Care system using cellular phones and the internet. *Diabet Med*, 26(6): 628-635.